Buy One Get One free -Llimited Time Offer X
Telmitime A, a prescription drug, is manufactured in various forms such as Tablet. Other than this, Telmitime A has some other therapeutic uses, which have been discussed ahead.
Medical history of the patient along with age and gender determines the dosage of Telmitime A. Dosage also depends on the route of administration and your chief complaint for which the drug is prescribed. Detailed information has been provided in the dosage section.
The most common side effects of Telmitime A are Headache, Dizziness, Palpitations (fluttering in chest). Some other side effects of Telmitime A have been listed ahead. Such side effects of Telmitime A normally do not last long and go away once the treatment is completed. If, however, they worsen or do not go away, please speak with your physician.
In addition, Telmitime A's effect is Severe during pregnancy and Severe for lactating mothers. In addition, Telmitime A's effects on the liver, heart and kidney are discussed below in the Telmitime A related warnings section.
Individuals suffering from medical conditions like Congestive Heart Failure (CHF), Coronary Artery Disease (CAD), Angioedema must refrain from the use of Telmitime A since this can cause severe adverse effects.
Drug interactions for Telmitime A have been reported in the medical literature. Refer to the list below for further details.
Along with the above-mentioned precautions, remember that taking Telmitime A is considered not safe while driving, and is not addictive.
Telmitime A is used to treat the following -
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult |
|
Geriatric |
|
Based on research, the following side effects have been observed when Telmitime A is used -
Severe
Common
Is the use of Telmitime A safe for pregnant women?
Telmitime A can cause severe side effects if taken during pregnancy, so, pregnant women should talk to their doctor before taking it.
Is the use of Telmitime A safe during breastfeeding?
Telmitime A should not be taken without taking your doctor's advice, as it may have severe side effects on breastfeeding women.
What is the effect of Telmitime A on the Kidneys?
Kidney can be affected by Telmitime A. If you experience any unwanted effects of this drug, stop taking it. You should take it again only after medical advice.
What is the effect of Telmitime A on the Liver?
The liver can be affected by Telmitime A. If you experience any unwanted effects of this drug, stop taking it and consult your doctor. You should restart Telmitime A only after medical advice.
What is the effect of Telmitime A on the Heart?
Telmitime A can have moderate side effects on the heart. If you notice any harmful effects then stop taking this drug right away. Consult your doctor before using this medicine again.
Telmitime A should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
If you are suffering from any of the following diseases, you should not take Telmitime A unless your doctor advises you to do so -
Is this Telmitime A habit forming or addictive?
No, there is no any evidence that Telmitime A is addictive.
Is it safe to drive or operate heavy machinery when consuming?
After taking Telmitime A you may feel sleepy. So it is not advised to perform these activities.
Is it safe?
Yes, but consume Telmitime A only on doctor's advice.
Is it able to treat mental disorders?
No, Telmitime A is not used to treat mental disorders.
Interaction between Food and Telmitime A
Due to a lack of research, nothing can be said about the consequences of taking Telmitime A together with food.
Interaction between Alcohol and Telmitime A
No research has been done on this till date. Therefore, it is not known what the effect of taking Telmitime A with alcohol will be.
Yes, it is safe to take Telmitime A as long as it is prescribed by your doctor. However, in some people, it may cause some side effects like back pain, sinusitis, and diaarhea.
No, Telmitime A doesn't cause a headache. However, if you experience a headache while using Telmitime A, please consult your doctor without any delay.
No, Telmitime A doesn't cause depression. However, if you experience depression while taking Telmitime A, please talk to your doctor immediately.
No, Telmitime A does not cause weight gain. Weight gain has rarely been associated with this drug. However, if you are experiencing unusual weight gain and you are in doubt that Telmitime A is causing weight gain then discuss with your doctor instantly.
Telmitime A is the brand name for telmisartan. It belongs to a group of medications known as angiotensin II receptor blockers. It is available in the form of tablets. Telmitime A is used to treat hypertension. It is also used to decrease cardiovascular risk in patients who cannot take ACE (angiotensin-converting enzyme) inhibitors.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 169-173
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 507
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Micardis® (telmisartan)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Twynsta® (telmisartan/amlodipine)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Norvasc® (amlodipine besylate)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 540, 549, 550
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 147-148